title: Recombinant probiotic therapy in experimental colitis in mice.
abstract: Recently, high interest has been attracted           to the research of inflammatory bowel diseases           (IBD). Recombinant probiotic bacteria may represent           an interesting way to influence the course of           IBD. Their benefits include cheap and simple production           and easy manipulation of the genetic material.           Several gene therapy and probiotic approaches           already showed promising results in the past. The           aim of this study was to test the probiotic potential of           IL-10-expressing Escherichia coli Nissle 1917 in a mouse           model of IBD and to compare it with control bacterial           strains. The dextran sulphate sodium (DSS)           model of colitis was examined for this purpose. Animals           received control probiotic bacteria or modified           probiotics (expressing IL-10) via gastric gavage.           Body weight, stool consistency, food and water consumption           were monitored. At the end of the experiment,           the parameters of inflammation, oxidative           stress and carbonyl stress were analysed in the samples           and statistical analysis was performed. We prepared           an anti-inflammatory probiotic Escherichia           coli strain that we designated Nissle 1917/pMEC-IL10           and proved its anti-inflammatory properties, which           are similar to those of the control probiotic strains           Nissle 1917 and Lactococcus lactis/pMEC-IL10 in vivo.           The probiotic therapy was successful according to           several parameters, including colon length, and oxidative           and carbonyl stress. Bacterially produced           IL-10 was detected in the plasma. The potential of           bacterial anti-inflammatory therapy of IBD using           modified probiotics           was outlined. The results opened           a way for upcoming studies using modified probiotics           for therapy of systemic diseases.
authors: Institute of Molecular Biomedicine, Comenius University, Bratislava, Slovak Republic. romangardlik@gmail.com
authors: R
authors: R
authors: Gardlik
authors: R
authors: R
authors: Palffy
authors: P
authors: P
authors: Celec
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003092:Colitis / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology* / Q000473:pathology; D003106:Colon / Q000187:drug effects / Q000473:pathology; D004195:Disease Models, Animal; D005243:Feces / Q000382:microbiology; D019270:Fructosamine / Q000378:metabolism; D016753:Interleukin-10 / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018384:Oxidative Stress / Q000187:drug effects; D019936:Probiotics / Q000494:pharmacology / Q000627:therapeutic use*; D050050:Protein Carbonylation / Q000187:drug effects; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D016753:Interleukin-10; D019270:Fructosamine; D008315:Malondialdehyde